drugset / Trial / NCT01341405
Study of CG100649 Versus Celecoxib in Osteoarthritis Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a double-blind, randomized, multicenter, phase 2b, noninferiority comparison of two active dose levels of CG100649 vs. a standard anti-arthritic dose of celecoxib (Celebrex).
Timeline
- Start
- 2011-04
- Primary completion
- 2011-12
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Celecoxib | Other / unclassified | 200 mg | Oral |
| Subject | Polmacoxib | Other / unclassified | 2 mg | Oral |
| Subject | Polmacoxib | Other / unclassified | 4 mg | Oral |